These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34948390)

  • 1. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.
    Peralta-Garcia A; Torrens-Fontanals M; Stepniewski TM; Grau-Expósito J; Perea D; Ayinampudi V; Waldhoer M; Zimmermann M; Buzón MJ; Genescà M; Selent J
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
    Chan SW; Shafi T; Ford RC
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
    Choi R; Zhou M; Shek R; Wilson JW; Tillery L; Craig JK; Salukhe IA; Hickson SE; Kumar N; James RM; Buchko GW; Wu R; Huff S; Nguyen TT; Hurst BL; Cherry S; Barrett LK; Hyde JL; Van Voorhis WC
    PLoS One; 2021; 16(4):e0250019. PubMed ID: 33886614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
    Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
    SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
    Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
    Watashi K
    Biochem Biophys Res Commun; 2021 Jan; 538():137-144. PubMed ID: 33272566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.
    Grau-Expósito J; Perea D; Suppi M; Massana N; Vergara A; Soler MJ; Trinite B; Blanco J; García-Pérez J; Alcamí J; Serrano-Mollar A; Rosado J; Falcó V; Genescà M; Buzon MJ
    PLoS Pathog; 2022 Jan; 18(1):e1010171. PubMed ID: 35025963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
    Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.
    Dittmar M; Lee JS; Whig K; Segrist E; Li M; Kamalia B; Castellana L; Ayyanathan K; Cardenas-Diaz FL; Morrisey EE; Truitt R; Yang W; Jurado K; Samby K; Ramage H; Schultz DC; Cherry S
    Cell Rep; 2021 Apr; 35(1):108959. PubMed ID: 33811811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Touret F; Driouich JS; Cochin M; Petit PR; Gilles M; Barthélémy K; Moureau G; Mahon FX; Malvy D; Solas C; de Lamballerie X; Nougairède A
    Antiviral Res; 2021 Sep; 193():105137. PubMed ID: 34265358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing Nucleoside Analogs for Human Coronaviruses.
    Zandi K; Amblard F; Musall K; Downs-Bowen J; Kleinbard R; Oo A; Cao D; Liang B; Russell OO; McBrayer T; Bassit L; Kim B; Schinazi RF
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33122172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
    Glebov OO
    FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
    Imamura K; Sakurai Y; Enami T; Shibukawa R; Nishi Y; Ohta A; Shu T; Kawaguchi J; Okada S; Hoenen T; Yasuda J; Inoue H
    FEBS Open Bio; 2021 May; 11(5):1452-1464. PubMed ID: 33822489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
    Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.
    Jang WD; Jeon S; Kim S; Lee SY
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34234012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
    Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
    Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
    Andrew M; Jayaraman G
    Carbohydr Res; 2021 Jul; 505():108326. PubMed ID: 34015720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.